Home » Archive

News

Drug Development, News, Syndication, Xconomy »

SD Biotech Roundup: Elevation Pharmaceuticals, BioSurplus, and More

Posted by sandiegobiotech May 17th, 2012 .
No Comments
We’re anticipating a lot of news out of a big cancer conference that begins next week in Chicago. Here is your head start. —Cancer researchers have talked for decades about finding the silver bullet...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Xconomist of the Week: Tom Maniatis on Prize4Life and ALS Research

Posted by sandiegobiotech May 17th, 2012 .
No Comments
A few years back, molecular geneticist Tom Maniatis was approached by a Harvard Business School student with a heart-wrenching story. The student, Avichai Kremer, then 29, had been diagnosed with...

[[Click headline to continue reading.]] More...

Marketwire, News, Syndication »

Second Parathyroid Hormone (PTH) Peptide Drug Patent Awarded to Aegis Therapeutics for Compositions Suitable for Metered Nasal Spray, Oral, and Injectable Delivery

Posted by Mary Canady May 16th, 2012 .
No Comments

SAN DIEGO, CA--(Marketwire - May 16, 2012) - Aegis Therapeutics LLC announced today that it has been awarded a second patent, U.S. Patent, No. 8,173,594, providing PTH and PTH analog compositions having increased stability and reduced aggregation and aggregation-associated immunogenicity. The stabilized formulations of parathyroid hormone (PTH) and PTH peptide analogs incorporate Aegis' Intravail®/ProTek® excipients suitable for all routes of administration including the non-invasive metered nasal spray delivery route or injection. Intravail® and ProTek® excipients allow for non-invasive delivery with high efficiency and stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding the oxidative damage caused by polysorbate surfactants currently found in many protein injectable drugs.

This patent, along with US Patent 8,076,290, has been exclusively licensed to Azelon Pharmaceuticals. All currently approved PTH drug formulations require daily injection. In contrast, Azelon has reported clinical results demonstrating that formulations of teriparatide based upon Aegis' Intravail®/ProTek® show excellent nasal bioavailability offering the prospect of a "first in class" non-injectable PTH drug. Non-injectable dosage forms of previously injectable-only drugs provide greater patient convenience and acceptance, improved compliance, and avoidance of needle-stick injury and disposal problems associated with the use of needles, paving the way to increased market share and substantial growth in overall product sales.

Licenses for non-invasive delivery and stabilization of human growth hormone; GLP-1 analogs; alpha, beta, and gamma interferon; and other drugs are currently available from Aegis with additional patent issuances to be announced shortly.

About Aegis Therapeutics

Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. For more information about Aegis, please visit: http://www.aegisthera.com.

More...

News, Syndication, UCSD News »

First Look at UC San Diego’s 8th Chancellor, Pradeep Khosla

Posted by Mary Canady May 16th, 2012 .
No Comments

In his first interview as the Chancellor-Designate, Khosla articulated his passion for students and higher education, his commitment to shared governance at UC San Diego, and his excitement about being our next leader. More...

News, Syndication, UCSD News »

UC San Diego Biologists Produce Potential Malarial Vaccine from Algae

Posted by Mary Canady May 16th, 2012 .
No Comments

UC San Diego biologists have produced a potential malarial vaccine from algae, an achievement that could pave the way for the development of an inexpensive way to protect billions of people from the disease.

More...

News, Syndication, UCSD News »

New Understanding of ‘Copper Pump’ in Cells Could Prime Discovery of Anti-Cancer Drugs

Posted by Mary Canady May 16th, 2012 .
No Comments

A team of University of California, San Diego researchers has made new discoveries about a copper-transporting protein in the membranes of human cells that drug-discovery scientists can co-opt for the development of new anti-cancer drugs.

More...

News, Syndication, UCSD News »

Girl Child Marriages Decline In South Asia, But Only Among Youngest

Posted by Mary Canady May 16th, 2012 .
No Comments

Each year, more than 10 million girls under the age of 18 marry, usually under force of local tradition and social custom. Almost half of these compulsory marriages occur in South Asia. A new study suggests that more than two decades of effort to eliminate the practice has produced mixed results.

More...

News, Syndication, UCSD News »

Rady School of Management Celebrates Opening of Wells Fargo Hall

Posted by Mary Canady May 16th, 2012 .
No Comments

The Rady School of Management celebrated the opening of Wells Fargo Hall Friday, a significant milestone for the school that has experienced extraordinary success and growth since its founding in 2003. More...

News, Syndication, Xconomy »

Targeted Cancer Drugs With Punch: The Next Big Class of Antibodies

Posted by sandiegobiotech May 16th, 2012 .
No Comments
[Updated: 1:30 pm PT, 5/17/12] One of the big dreams in biotech over the past 35 years has been to make drugs that work like “smart bombs” by destroying tumors while minimizing collateral damage....

[[Click headline to continue reading.]] More...

News, Syndication, UCSD News »

From Satellites to Chocolates to a Countless Other Industries, UC San Diego Alumni Make an Impact

Posted by Mary Canady May 15th, 2012 .
No Comments
Last October, on an observation deck about eight kilometers from the Baikonur Cosmodrome in Kazakhstan, ViaSat co-founder and chief technology officer Mark Miller, a graduate of UC San Diego, waited nervously for the countdown to commence. More...